Review
Nature Reviews Drug Discovery 7, 221-230 (February 2008) | doi:10.1038/nrd2519
Genome-wide association studies: progress and potential for drug discovery and development
Stephen F. Kingsmore1, Ingrid E. Lindquist1, Joann Mudge1, Damian D. Gessler1 & William D. Beavis1 About the authors
Abstract
Although genetic studies have been critically important for the identification of therapeutic targets in Mendelian disorders, genetic approaches aiming to identify targets for common, complex diseases have traditionally had much more limited success. However, during the past year, a novel genetic approach — genome-wide association (GWA) — has demonstrated its potential to identify common genetic variants associated with complex diseases such as diabetes, inflammatory bowel disease and cancer. Here, we highlight some of these recent successes, and discuss the potential for GWA studies to identify novel therapeutic targets and genetic biomarkers that will be useful for drug discovery, patient selection and stratification in common diseases.
- View At a Glance
Author affiliations
- National Center for Genome Resources, 2935 Rodeo Park Drive East, Santa Fe, New Mexico 87505, USA.
Correspondence to: Stephen F. Kingsmore1 Email: sfk@ncgr.org
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Guilt beyond a reasonable doubtNature Genetics News and Views (01 Jul 2007)
Islands of linkage disequilibriumNature Genetics News and Views (01 Oct 2001)
See all 3 matches for News And ViewsRESEARCH
Genetic basis of salt-susceptibility in the Sabra rat model of hypertensionKidney International Original Article
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controlsNature Article (07 Jun 2007)
See all 30 matches for Research

